Sunshine Biopharma Inc
SBFM1.200USD
+0.050+4.35%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
5.47MMarket Cap
0.23P/E TTM
More Details of Sunshine Biopharma Inc Company
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Sunshine Biopharma Inc Info
Ticker SymbolSBFM
Company nameSunshine Biopharma Inc
IPO dateAug 15, 2008
CEOSlilaty (Steve N)
Number of employees52
Security typeOrdinary Share
Fiscal year-endAug 15
Address333 Las Olas Way
CityFORT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone19543300684
Websitehttps://www.sunshinebiopharma.com/
Ticker SymbolSBFM
IPO dateAug 15, 2008
CEOSlilaty (Steve N)
Company Executives of Sunshine Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Operating Officer, Director
Chief Operating Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
Other
92.67%
Shareholders
Shareholders
Proportion
L1 Global Manager Pty Limited
2.90%
Citadel Advisors LLC
1.59%
Renaissance Technologies LLC
1.14%
DRW Securities, LLC
0.92%
Two Sigma Investments, LP
0.79%
Other
92.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.94%
Hedge Fund
3.51%
Research Firm
0.10%
Individual Investor
0.04%
Other
92.41%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
370.31K
7.55%
-134.73K
2025Q3
33
128.14K
2.61%
-276.56K
2025Q2
40
174.71K
3.84%
-217.75K
2025Q1
40
223.71K
4.97%
+181.45K
2024Q4
39
166.72K
8.34%
+112.42K
2024Q3
38
41.53K
13.09%
+24.77K
2024Q2
37
17.39K
14.86%
+11.35K
2024Q1
40
9.43K
19.69%
+5.56K
2023Q4
38
3.43K
26.72%
+270.00
2023Q3
34
2.71K
21.06%
-1.08K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
L1 Global Manager Pty Limited
142.24K
2.9%
+139.60K
+5281.91%
Dec 31, 2024
Citadel Advisors LLC
78.09K
1.59%
+14.66K
+23.11%
Sep 30, 2025
Renaissance Technologies LLC
55.70K
1.14%
+1.61K
+2.97%
Sep 30, 2025
DRW Securities, LLC
44.98K
0.92%
+44.98K
--
Sep 30, 2025
Two Sigma Investments, LP
38.58K
0.79%
+38.58K
--
Sep 30, 2025
SBI Securities Co., Ltd.
4.85K
0.1%
-1.84K
-27.55%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
3.83K
0.08%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
206.00
0%
--
--
Sep 30, 2025
Chamoun (Malek)
1.85K
0.04%
--
--
Oct 17, 2025
Osaic Holdings, Inc.
152.00
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Date
Ex-dividend Date
Type
Ratio
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Aug 06, 2024
Merger
20→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
Apr 12, 2024
Merger
100→1
